

1 August 2023

ASX Announcement

Update on Nasodine Phase 2 Study

Firebrick Pharma Limited (ASX:FRE) (Firebrick, Company) advises the market that despite earlier expectations (ASX announcement 12 July 2023) that results of its Phase 2 COVID-19 shedding study would be available by the end of July, the statistical analysis of the trial results is not yet complete. The Company will communicate the results as soon as accurate and complete results are available.

This announcement was authorised for release by Dr Peter Molloy, Executive Chairman, Firebrick Pharma Limited.

- ENDS -

About Firebrick (ASX:FRE)

Firebrick is a pharmaceutical company founded in 2012 with the mission to develop and commercialise a nasal spray treatment for the common cold based around the potential of povidone-iodine as a broad-spectrum antimicrobial agent. The Company owns numerous granted and pending patents, including a core patent family that covers the use of intranasal povidone-iodine for the treatment and prevention of the common cold and a second patent family covering the prevention of pandemic viral diseases, including COVID-19. Firebrick is currently completing a second Phase 3 trial for Nasodine, to confirm its efficacy as a treatment for the common cold and support international partnering and approvals.

Media enquiries:

Heidi Cuthbert
+61 411 272 366
heidi.cuthbert@multiplier.com.au

Investor enquiries:

Investors@firebrickpharma.com